12 Month Price Forecast For LBPH
Distance to LBPH Price Forecasts
LBPH Price Momentum
🤔 Considering Longboard Pharma (LBPH)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 2:52 PM UTC
LBPH Analyst Ratings & Price Targets
Based on our analysis of 11 Wall Street analysts, LBPH has a consensus that is neutral. The median price target is $64.00, with forecasts ranging from $60.00 to $68.00. Currently, there are 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
With LBPH currently trading at $59.98, the median price forecast suggests a 6.7% upside. The most optimistic forecast comes from at , projecting a 13.4% upside, while Patrick Trucchio at HC Wainwright & Co. provides the most conservative target, suggesting a 0.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LBPH Analyst Consensus
LBPH Price Target Range
Latest LBPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LBPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 15, 2024 | HC Wainwright & Co. | Patrick Trucchio | Neutral | Downgrade | $60.00 |
| Oct 15, 2024 | Truist Securities | Joon Lee | Hold | Downgrade | $60.00 |
| Oct 14, 2024 | B. Riley Securities | Kalpit Patel | Neutral | Downgrade | $60.00 |
| Oct 14, 2024 | Cantor Fitzgerald | Josh Schimmer | Neutral | Downgrade | $0.00 |
| Sep 18, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $80.00 |
| Sep 17, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $44.00 |
| Sep 16, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $90.00 |
| Sep 10, 2024 | Truist Securities | Joon Lee | Buy | Initiates | $60.00 |
| Aug 26, 2024 | Evercore ISI Group | Josh Schimmer | Outperform | Maintains | $80.00 |
| Aug 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Aug 5, 2024 | B. Riley Securities | Kalpit Patel | Buy | Maintains | $45.00 |
| Aug 2, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $40.00 |
| Aug 2, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $90.00 |
| Aug 2, 2024 | Citigroup | David Hoang | Buy | Maintains | $50.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Jul 11, 2024 | Baird | Joel Beatty | Outperform | Maintains | $60.00 |
| Jul 2, 2024 | Citigroup | David Hoang | Buy | Maintains | $45.00 |
| Jul 2, 2024 | Evercore ISI Group | Josh Schimmer | Outperform | Maintains | $80.00 |
| Jun 20, 2024 | Evercore ISI Group | Josh Schimmer | Outperform | Maintains | $57.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $60.00 |
Longboard Pharmaceuticals, Inc. (LBPH) Financial Data
Longboard Pharmaceuticals, Inc. has a market capitalization of $2.34B with a P/E ratio of -25.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -46.7%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Longboard Pharmaceuticals, Inc. (LBPH) Company Overview
About Longboard Pharmaceuticals, Inc.
Develops transformative medicines for neurological diseases.
Longboard Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on the research and development of innovative therapies for neurological conditions. The company generates potential revenue through the successful advancement of its drug candidates, such as bexicaserin and LP659, through clinical trials, ultimately aiming for regulatory approval and commercialization.
Founded in 2020 and based in La Jolla, California, Longboard Pharmaceuticals was previously known as Arena Neuroscience, Inc. The company is dedicated to addressing unmet medical needs in the field of neurology, particularly for conditions like developmental and epileptic encephalopathies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
50
CEO
Mr. Kevin R. Lind
Country
United States
IPO Year
2021
Website
www.longboardpharma.comLongboard Pharmaceuticals, Inc. (LBPH) Latest News & Analysis
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
1 month agoLongboard Pharmaceuticals (Nasdaq: LBPH) has begun a global Phase 3 study for bexicaserin, targeting seizures in patients with Developmental and Epileptic Encephalopathies (DEEs).
Longboard Pharmaceuticals' Phase 3 study for bexicaserin could significantly impact its stock value, depending on trial results, as successful outcomes may lead to market approval and revenue potential.
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
1 month agoLongboard Pharmaceuticals (Nasdaq: LBPH) announced a strategic acquisition by H. Lundbeck A/S and reported Q3 2024 financial results, focusing on its candidate Bexicaserin for neurological diseases.
Longboard Pharmaceuticals' acquisition by Lundbeck could indicate strong future growth and validation of its drug pipeline, impacting stock performance and investor confidence.
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH
1 month agoFormer Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating Longboard Pharmaceuticals' proposed sale to H. Lundbeck A/S for $60 per share to assess if the offer is adequate.
The investigation into Longboard Pharmaceuticals' sale to Lundbeck could affect the stock's price and shareholder value, signaling potential legal and valuation risks for investors.
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. - LBPH
1 month agoMonteverde & Associates PC is investigating Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) concerning a tender offer, having a reputation for recovering funds for shareholders.
The investigation into Longboard Pharmaceuticals could indicate potential legal or financial issues, affecting stock price and investor sentiment. Recovery for shareholders may influence future class actions.
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
1 month agoLBPH stock increased 52% following the announcement of its acquisition by Lundbeck for $2.6 billion to enhance Lundbeck's neuro pipeline.
LBPH's 52% stock surge reflects investor optimism over the acquisition by Lundbeck, enhancing its neuro pipeline and potentially increasing future revenue and market value.
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. – LBPH
1 month agoMonteverde & Associates is investigating Longboard Pharmaceuticals (Nasdaq: LBPH) regarding H. Lundbeck A/S's tender offer to acquire shares at $60.00 each.
The tender offer at $60 per share from H. Lundbeck for Longboard Pharmaceuticals signals a potential premium for investors, influencing stock valuation and future investment strategies.
Frequently Asked Questions About LBPH Stock
What is Longboard Pharmaceuticals, Inc.'s (LBPH) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Longboard Pharmaceuticals, Inc. (LBPH) has a median price target of $64.00. The highest price target is $68.00 and the lowest is $60.00.
Is LBPH stock a good investment in 2025?
According to current analyst ratings, LBPH has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $59.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for LBPH stock?
Wall Street analysts predict LBPH stock could reach $64.00 in the next 12 months. This represents a 6.7% increase from the current price of $59.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Longboard Pharmaceuticals, Inc.'s business model?
Longboard Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on the research and development of innovative therapies for neurological conditions. The company generates potential revenue through the successful advancement of its drug candidates, such as bexicaserin and LP659, through clinical trials, ultimately aiming for regulatory approval and commercialization.
What is the highest forecasted price for LBPH Longboard Pharmaceuticals, Inc.?
The highest price target for LBPH is $68.00 from at , which represents a 13.4% increase from the current price of $59.98.
What is the lowest forecasted price for LBPH Longboard Pharmaceuticals, Inc.?
The lowest price target for LBPH is $60.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 0.0% increase from the current price of $59.98.
What is the overall LBPH consensus from analysts for Longboard Pharmaceuticals, Inc.?
The overall analyst consensus for LBPH is neutral. Out of 11 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $64.00.
How accurate are LBPH stock price projections?
Stock price projections, including those for Longboard Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
